Detail akcie Nuvalent Rg-A online

Business Summary: Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Nuvalent Inc revenues was not reported. Net loss increased 65% to $306.7M. Higher net loss reflects Biopharmaceuticals segment loss increase from $117.7M to $312.1M, United States segment loss increase from $117.7M to $312.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.86 to -$4.27.